Aperio Group’s Albireo Pharma Inc ALBO Stock Holding History

Aperio Group’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,306	Closed	-$42K	–	2877
2019 Q2	$42K	Buy	+1,306	New	+$43.7K	﹤0.01%	2567

Other funds holding ALBO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aperio Group's ALBO Position: Q3 2019 in Review

Aperio Group sold out of Albireo Pharma Inc (ALBO) in Q3 2019, closing a stake of 1,306 shares — an estimated $42K sold.

Aperio Group first reported a position in ALBO in Q2 2019 and held it in 1 quarter. The position peaked at $42K in Q2 2019. 69 funds tracked by Wall St. Rank hold ALBO as of Q3 2019.

Aperio Group reported no remaining Albireo Pharma Inc position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 1,306 Albireo Pharma Inc shares in Q3 2019, an estimated $42K.
Aperio Group first reported a position in Albireo Pharma Inc in Q2 2019 and held it in 1 quarter.
Aperio Group's Albireo Pharma Inc position peaked at $42K in Q2 2019.
69 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.